Advertisement

Topics

MD Anderson and Pfizer Collaborate to Evaluate Immuno-Oncology Combinations in Blood Cancers and Solid Tumors

09:30 EDT 27 Sep 2017 | Speciality Pharma Journal

The University of Texas MD Anderson Cancer Center and Pfizer Inc.  today announced that they have entered into a clinical collaboration to study novel combinations of three Pfizer investigational immuno-oncology therapies and other Pfizer agents in the treatment of various solid tumors and hematologic malignancies. “This alliance aims to define patients with solid tumors who may …

Original Article: MD Anderson and Pfizer Collaborate to Evaluate Immuno-Oncology Combinations in Blood Cancers and Solid Tumors

NEXT ARTICLE

More From BioPortfolio on "MD Anderson and Pfizer Collaborate to Evaluate Immuno-Oncology Combinations in Blood Cancers and Solid Tumors"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...